Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Ottawa Hospital Research Institute
$120,000.00
Development of Combinatorial Therapy for the Treatment of Spinal Muscular Atrophy
EF 2025-26
Résumé
Spinal muscular atrophy (SMA) is a devastating neuromuscular disease, caused by a genetic mutation that prevents the body from producing vital SMN protein. Without adequate SMN protein, motor neurons in the spinal cord die. Without motor neurons, the brain and spinal cord are unable to communicate with muscles, leading to weakness, paralysis and early death. While current therapies are able to improve strength and extend lifespan in many patients, some patients respond well to therapy while others do not. Even for those who respond well, treatment is only partially curative, and for this reason research must continue to explore new therapies and new combinations of therapies to better treat this debilitating disease.
Our lab is currently exploring the effects of a new genetic therapy that may boost SMN protein levels and provide a permanent fix for patients with SMA. We are testing this therapy using mice that have been engineered to have SMA. We are also exploring the effect of combining our new genetic therapy with two currently approved treatments to see if either combination can further increase SMN levels, prevent muscle weakness and restore mobility in our mice.
To evaluate the effect of our combination therapies, we treat the mice on their first day of life and after 2 weeks, measure the level of SMN protein in different tissues. Using a microscope, we count the number of motor neurons in the spinal cord to see if any have died and if they appear large and healthy. We look at how well connected the motor neurons are to muscle tissue, record if any connections are broken and look for other signs of disease. We measure the size of muscle fibers and look for signs of poor muscle development. Similar to in humans, we also assess walking ability in our mice and conduct a series of coordination tests.
Through analysis of this data we can determine how well our therapies prevent the onset of SMA and if either combination of therapies should be further studied.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
559293
Name
Yaworski Rebecca A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Development of Combinatorial Therapy for the Treatment of Spinal Muscular Atrophy
Programtype2
Studentship Programs
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Electrophysiology, Compound Muscle Action Potential; Evaluation Of Combinatorial Therapy In A Mouse Model Of Sma; Gene Replacement Therapy, Dose Escalation Study; In Vivo Testing Of Crispr Base Editor; International Collaboration, Canada And Usa; Motor Function Testing, Righting Reflex, Gait Analysis; Novel Therapy For The Treatment Of Spinal Muscular Atrophy; Phenotypic Analysis, Histopathology, Fluorescent Microscopy; Regenerative Medicine, Pediatric Neuromuscular Disorder; Translational Research
Abstract
Spinal muscular atrophy (SMA) is a devastating neuromuscular disease, caused by a genetic mutation that prevents the body from producing vital SMN protein. Without adequate SMN protein, motor neurons in the spinal cord die. Without motor neurons, the brain and spinal cord are unable to communicate with muscles, leading to weakness, paralysis and early death. While current therapies are able to improve strength and extend lifespan in many patients, some patients respond well to therapy while others do not. Even for those who respond well, treatment is only partially curative, and for this reason research must continue to explore new therapies and new combinations of therapies to better treat this debilitating disease.
Our lab is currently exploring the effects of a new genetic therapy that may boost SMN protein levels and provide a permanent fix for patients with SMA. We are testing this therapy using mice that have been engineered to have SMA. We are also exploring the effect of combining our new genetic therapy with two currently approved treatments to see if either combination can further increase SMN levels, prevent muscle weakness and restore mobility in our mice.
To evaluate the effect of our combination therapies, we treat the mice on their first day of life and after 2 weeks, measure the level of SMN protein in different tissues. Using a microscope, we count the number of motor neurons in the spinal cord to see if any have died and if they appear large and healthy. We look at how well connected the motor neurons are to muscle tissue, record if any connections are broken and look for other signs of disease. We measure the size of muscle fibers and look for signs of poor muscle development. Similar to in humans, we also assess walking ability in our mice and conduct a series of coordination tests.
Through analysis of this data we can determine how well our therapies prevent the onset of SMA and if either combination of therapies should be further studied.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Yaworski, Rebecca A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~